ICN Pharmaceuticals
Executive Summary
Proposed joint venture with the China National Medical Corp. covers the production of ribavirin in the Peoples Republic, where hepatitis and hemorrhagic fever -- both treated by the drug -- are endemic; some 100 mil. Chinese are estimated to carry some form of hepatitis virus. The joint venture will initially produce 10,000 kg of ribavirin annually, of which ICN will purchase at least 50%. ICN will also assist CNMC to improve marketing and distribution of the drug and to boost its acceptance in the medical community.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.